{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:05:44Z","timestamp":1780351544167,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ygyno.2021.01.039","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T07:34:29Z","timestamp":1612596869000},"page":"389-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1016","volume":"161","author":[{"given":"Laura M.","family":"Chambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Gruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chichura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"Costales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad M.","family":"Michener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Debernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.01.039_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer. J. Clin."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0010","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.3802\/jgo.2020.31.e58","article-title":"Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands","volume":"31","author":"Burg","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10585-019-10007-0","article-title":"Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes","volume":"37","author":"Gardner","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ygyno.2021.01.039_bb0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ygyno.2020.03.003","article-title":"Prognostic value of radiological recurrence patterns in ovarian cancer","volume":"157","author":"Roze","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0025","series-title":"NCCN clinical practice guideline in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. version 1.20","author":"Armstrong","year":"2020"},{"key":"10.1016\/j.ygyno.2021.01.039_bb0030","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin.Oncol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0045","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin.Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2021.01.039_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005340.pub3","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2011","journal-title":"Cochrane Database Syst. Rev"},{"key":"10.1016\/j.ygyno.2021.01.039_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","article-title":"Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy","volume":"127","author":"Esselen","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.01.039_bb0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","article-title":"Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery","volume":"106","author":"Bae","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2021.01.039_bb0070","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","article-title":"Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer","volume":"21","author":"Cascales-Campos","year":"2014","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.039_bb0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2021.01.039_bb0080","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.01.039_bb0085","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/ijgc-2020-001517","article-title":"Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer","volume":"30","author":"Kim","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.01.039_bb0090","article-title":"Primary site disease and recurrence location in ovarian cancer patients undergoing primary debulking surgery vs. interval debulking surgery","author":"Vito Andrea","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0095","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.3802\/jgo.2018.29.e53","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study, J","volume":"29","author":"Ceresoli","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0100","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ygyno.2020.06.487","article-title":"A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology","volume":"158","author":"Chambers","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/SLA.0b013e3181afde41","article-title":"The accordion severity grading system of surgical complications","volume":"250","author":"Strasberg","year":"2009","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2019.04.035","article-title":"Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse","volume":"221","author":"Hollis","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.01.039_bb0120","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am. J. Obstet. Gynecol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:46:43Z","timestamp":1715820403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0090825821000998"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.039","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}